Burn wounds are a global public health problem and a leading cause of morbidity, including prolonged hospitalisation, disfigurement and disability – often accompanied by stigma and social rejection.1 Our aim is to help mitigate the complications associated with burn wounds.
Prepare the wound bed
Target early excision as the gold standard for reducing the intensity of hypermetabolism and removing the biological environment for infection, thereby reducing the risk of sepsis.2
Accelerate your surgical debridement*3-5
Explore the VERSAJET◊ II Hydrosurgery System as a powerful surgical tool to help:
Provide a smoother, more regular and consistent wound bed (ready to receive a skin graft)*6
Disrupt and remove biofilm from contaminated tissue, helping to prevent bacteria or biofilm from reforming and causing localised infection**7
Precisely and safely debride burned necrotic tissue (superficial and intermediate depth)8 and other unwanted material from the wound surface, and help preserve viable tissue.9,10
Protect from infection
Consider the use of a topical antimicrobial to help slow the process of sepsis; shown to be instrumental in preventing larger, more severe burns from succumbing to sepsis.2
Fast and effective protection11-14
Use ACTICOAT◊ Antimicrobial Barrier Dressings to help minimise the risk of infection in paediatric and adult patients.
Fast-acting to kill bacteria in as little as 30 minutes***15-20
Effective against a broad spectrum of bacterial and fungal wound pathogens***15,16,21,22
Conformable to anatomical areas and help minimise trauma to the wound on dressing removal26,27 23,24
Rehydrate tissue
Use INTRASITE◊Gel and INTRASITE Conformable Hydrogel Wound Dressings in conjunction with ACTICOAT Dressings.
Progress to healing
Support re-epithelialisation with the use of temporary skin substitutes2 and considerthe use of tradition or single-use negative pressure wound therapy (NPWT).
Choose a suitable pathway
For extensive body surface areas: BIOBRANE◊ Temporary Biosynthetic Wound Dressings are easy to apply25-29 and conform to surfaces to allow joint movement.28,30 Suitable for paediatric patients,28,31,32 they may require a limited number of dressing changes compared to standard care33,34
*Compared to sharp debridement.
**As demonstrated in vivo.
***As demonstrated in vitro.
Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Smith+Nephew representative or distributor if you have questions about the availability of Smith+Nephew products in your area. For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product’s applicable Instructions for Use (IFU) prior to use.
1.Burns. World Health Organization. Updated March 6th, 2018. Accessed March 17th, 2023. https://www.who.int/news-room/fact-sheets/detail/burns#:~:text=An%20estimated%20180%20000%20deaths,in%20the%20home%20and%20workplace
2. Marc G. Jeschke, et al. Nat Rev Dis Primers. 2020 Feb 13;6(1):11.
3. Caputo WJ, et al. Int Wound J. 2008;5(2):288–294.
4. Liu J, et al. Int Wound J. 2015;12(4):456–461.
5. McAleer JP, Kaplan EM, Perisich G, Axman W. A Prospective Randomized Study Evaluating the Time Efficiency of the VERSAJET™ Hydrosurgery System and Traditional Wound Debridement. Poster presented at: ACFAS 2005; New Orleans, LA.
6. Vanwiljck R, et al. J Plast, Reconstr & Aesthetic Surg. 2010;63:544–549.
7. Allan N. In Abstracts 20th Meeting of the European Tissue Repair Society, 2010; 9, 77–98.
8. Rennekampff HA, et al. Burns. 2006;32(1):64–69.
9. Hyland EJ, et al. Burns. 2015;41(4):700–707.
10. Matsumura H,. Annal Plast Surg. 2012;69(5):521–525.
11. Gago M,. Wounds. 2008;20(10):273–278.
12. Tredget EE, et al. J Burn Care Rehabil. 1998;19(6):531–537.
13. Strohal R, et al. J Hosp Infect. 2005;60(3):226–230.
14. Chaloner D, et al. A comparative study of two silver containing dressings, ACTICOAT 7 and Avance, in the treatment of chronic venous ulcers. Poster presented at: WUWHS2004; Paris.
15. Wright JB, et al. Am J Infect Control. 1998;26(6):572–577.
16. Wright JB, et al. Am J Infect Control. 1999;27(4):344–350.
17. Smith+Nephew 2008.. Internal Report. DOF 0810018.
18. Smith+Nephew 2008.. Internal Report. DOF 0810014.
19. Yin HQ, et al. J Burn Care Rehabil. 1999;20(3):195–200.
20. Wright JB, et al. Wounds. 1998;10(6):179–188.
21. Smith+Nephew 2008. Internal Report. DOF 0810016.
22. Smith+Nephew 2008. Internal Report. DOF 0810012. 23
23. Smith+Nephew 2011. Internal Report. SR/CE/036/ACB. 26
24. Smith+Nephew 2011. Internal Report. SR/CIME/017. 27
25. Erdman D, et al. Burns. 1996;22(2):141–146.
26. Lo CH, et al. J Plast Reconstr Aesthet Surg. 2019;72(3):427–437.
27. Muganza A, et al.. Glob J Med Res. 2014;14(6):5–12.
28. Lesher AP, et al. J Pediatr Surg. 2011;46(9):1759–1763.
29. Austin RE, et al. Burns. 2015;41(4):749–753.
30. Farroha A, et al. Ann Burns Fire Disasters. 2013;XXVI(2):94–97.
31. Muganza A, et al. Glob J Med Res. 2014;14(6):5–12.
32. Cassidy C, et al. Burns. 2005;31(7):890–893.
33. Lang EM, et al. Ann Plast Surg. 2005;55(5):485–489.
34. Lal S, Barrow RE, et al. Shock (Augusta, Ga). 2000;14(3):314–318; 318–319.
35. Dunn R, et al. Int J Surg. 2011;9(3):258–262.
36. Chan SYC, et al. Diabet Foot Ankle. 2014;17(5):1–7.
37. Young SR, Hampton S, Martin R. Int Wound J. 2013;10(4):383-388.
41 Forle M, et al. A randomised controlled trial to compare the clinical efficacy and acceptability of adjustable intermittent and continuous Negative Pressure Wound Therapy (NPWT) in a new portable NPWT system. Poster presented at: European Wound Management Association (EWMA)2018.
42. Birke-Sorensen H, et al. J Plast Reconstr Aesthet Surg. 2011;64(1):S1–S16.
43. Young SR, et al. Int Wound J. 2013;10(4):383–388.
44. Canonico S, et al. Acta Vulnol. 2012;10(2):57–66.
45. Smith+Nephew 2020. Internal Report. 2001002.
46. Hudson DA, et al. Int Wound J. 2015;12(2):195–201.
Text